Agency Information Collection Activities; Proposed Collection; Comment Request; Tobacco Products Subject to the Federal Food, Drug, and Cosmetic Act
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA, we, or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on "Tobacco Products Subject to the Federal Food, Drug, and Cosmetic Act."
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 82 (Thursday, April 28, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 82 (Thursday, April 28, 2022)]
[Notices]
[Pages 25280-25282]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-09072]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-0305]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Tobacco Products Subject to the Federal Food, Drug,
and Cosmetic Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, we, or Agency) is
announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act
of 1995 (PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on ``Tobacco Products Subject to
the Federal Food, Drug, and Cosmetic Act.''
DATES: Submit either electronic or written comments on the collection
of information by June 27, 2022.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before June 27, 2022. The <a href="https://www.regulations.gov">https://www.regulations.gov</a> electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of June 27, 2022. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to <a href="https://www.regulations.gov">https://www.regulations.gov</a>
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
<bullet> If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
<bullet> Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
<bullet> For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2019-N-0305 for ``Tobacco Products Subject to the Federal Food,
Drug, and Cosmetic Act.'' Received comments, those filed in a timely
manner (see ADDRESSES), will be placed in the docket and, except for
those submitted as ``Confidential Submissions,'' publicly viewable at
<a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets Management Staff between
9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
<bullet> Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: <a href="https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf</a>.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Jonnalynn Capezzuto, Office of
Operations, Food and Drug
[[Page 25281]]
Administration, Three White Flint North, 10A-12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301-796-3794, <a href="/cdn-cgi/l/email-protection#b6e6e4f7e5c2d7d0d0f6d0d2d798dedec598d1d9c0"><span class="__cf_email__" data-cfemail="217173607255404747614745400f4949520f464e57">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Tobacco Products Subject to the Federal Food, Drug, and Cosmetic Act
OMB Control Number 0910-0768--Extension
Tobacco products are governed by chapter IX of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (sections 900 through 920) (21 U.S.C.
387 through 21 U.S.C. 387t). Implementing regulations are found in 21
CFR subchapter K (21 CFR parts 1100 through 1150). This information
collection supports the reporting, recordkeeping, and third-party
disclosure requirements associated with statutory requirements
applicable to tobacco products and set forth in Agency regulations.
Section 910(a)(1) of the FD&C Act (21 U.S.C. 387j(a)(1)) defines a
``new tobacco product'' as a tobacco product that was not commercially
marketed in the United States on February 15, 2007, or a modification
(including a change in design, any component, any part, or any
constituent, including a smoke constituent, or in the content,
delivery, or form of nicotine, or any other additive or ingredient) of
a tobacco product where the modified product was commercially marketed
in the United States after February 15, 2007. An order under section
910(c)(1)(A)(i) of the FD&C Act is required prior to marketing a new
tobacco product. This requirement applies unless the product has been
shown to be substantially equivalent to a valid predicate product or is
exempt from substantial equivalence (21 CFR 1107.1).
Section 910(b) of the FD&C Act states that a premarket tobacco
application (PMTA) (21 CFR part 1114) shall contain full reports of all
investigations of health risks; a full statement of all components,
ingredients, additives, and properties, and of the principle or
principles of operation of such tobacco product; a full description of
methods of manufacturing and processing (which includes: a listing of
all manufacturing, packaging, and control sites for the product); an
explanation of how the product complies with applicable tobacco product
standards; samples of the product and its components; and labeling.
FDA also encourages persons who would like to study their new
tobacco product to meet with the Office of Science (OS) in the Center
for Tobacco Products (CTP) to discuss their investigational plan. The
request for a meeting should be sent in writing to the Director of
CTP's Office of Science and should include adequate information for FDA
to assess the potential utility of the meeting and to identify FDA
staff necessary to discuss agenda items. The following web page details
the process for requesting a meeting with OS and how FDA will respond:
<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meetings-industry-and-investigators-research-and-development-tobacco-products">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/meetings-industry-and-investigators-research-and-development-tobacco-products</a>.
FDA efforts regarding issuance of a final guidance for Harmful and
Potentially Harmful Constituent reporting (and later a testing and
reporting regulation under section 915 of the FD&C Act) is ongoing, and
the guidance document will be issued consistent with our Good Guidance
Practice regulations found in 21 CFR 10.115, which provide for public
comment at any time.
We estimate the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total annual burden per
Activity respondents responses per responses response (in Total hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Obtaining an FDA Order 200 3.75 750 1,713 1,284,750
Authorizing Marketing of
Tobacco Product (PTMA
application) and 21 CFR 25.40
Environmental Assessments......
Request for Meeting with CTP's 27 1 27 10 270
Office of Science to Discuss
Investigational Plan...........
Sec. 1143 Cigar Warning Plans. 1 1 1 1 1
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 1,285,021
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
FDA estimates an average burden per respondent of 1,500 hours to
prepare a PMTA seeking an order from FDA allowing the marketing of a
new tobacco product. We assume, on average, an additional 213 hours is
necessary to prepare an environmental assessment in accordance with the
requirements of 21 CFR 25.40, for a total of 1,713 hours per PMTA
application. This average represents a wide range of hours that will be
required for these applications
[[Page 25282]]
under different circumstances, with a small number requiring more hours
(e.g., as many as 5,000 hours for early applications that involve
complex products and for which the company has no experience conducting
studies or preparing analysis of public health impacts, or for which
reliance on master files is not possible) as well as many requiring
fewer hours (e.g., as few as 50 hours for applications for products
that are very similar to other new products). A PMTA may require one or
more types of studies including chemical analysis, nonclinical studies,
and clinical studies. FDA also estimates the number of PMTAs that FDA
expects to receive annually will be 750 (642 electronic nicotine
delivery systems (ENDS) Liquids and 108 ENDS Delivery Systems).
FDA anticipates that the 27 potential respondents to this
collection may need to meet with CTP's Office of Science to discuss
their investigational plans. This number has been reduced based on the
average number of meeting requests received over the past 3 years. To
request this meeting, applicants should compile and submit information
to FDA for meeting approval. FDA estimates that it will take
approximately 270 hours to compile and request a meeting with OS. We
have revised the hours per response to be consistent with the meetings
information collection for originally regulated products (OMB control
number 0910-0731).
Based on the September 2020 order vacating the health warning
requirements for cigars and pipe tobacco (set forth in Sec. Sec.
1143.3 and 1143.5) and remanding the Final Deeming Rule's warning
requirements for cigars and pipe tobacco, we have removed the burden
associated with this activity. We have included one token hour of
burden associated with the requirements in Sec. 1143 to acknowledge
the requirement remains in the regulations.
We have adjusted our burden estimate, which has resulted in a
decrease to the currently approved burden. The total estimated burden
for this information collection is 1,285,021 reporting hours, and 778
annual responses. Our estimated burden for the information collection
reflects an overall decrease of 2,779 hours and a corresponding
decrease of 262 responses. We attribute this adjustment to updated
information in the number of meeting requests with CTP's Office of
Science to discuss investigational plans, the removal of burden for the
cigar warning plans, the removal of the small-scale manufacturer
reporting, and have therefore revised the estimated burden and number
of respondents to the information collection.
Dated: April 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-09072 Filed 4-27-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.